AKT1 and neoplasm: Other Akt degraders, MS21 and MS143, which are von Hippel–Lindau (VHL)-recruiting PROTACs based on the Akt inhibitor AZD5363, induce rapid and robust Akt degradation leading to suppressing cancer cell growth and tumor growth in vivo in a xenograft model without causing apparent toxicity [152].